All had previously completed four cycles of Lu177-DOTATATE therapy. Approximately 5 miCu of Pb203-AR-RMX were injected by iv and both whole body scans and SPECT/CT scans of the abdomen were obtained. Blood and urine samples were collected up to 48 hours after injection for safety and pharmacokinetic assessment. Organ doses were calculated using the imaging data. No significant hematological or renal toxicity was observed.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Based on the Pb203-AR-RMX dosimetry, the expected doses for Pb212-AR-RMX are calculated and, as expected, the spleen receives the highest dose though the kidneys are the dose-limiting organ. The first clinical trials for Pb211-AR-RMX targeted alpha therapy are expected in the fourth quarter of 2017.
Presented By: Ebrahim S. Delpassand from RadioMedix Inc., USA
Written By: William Carithers, Lawrence Berkeley National Laboratory
at the 10th International Symposium on Targeted Alpha Therapy (TAT-10) May 31 - June 1, 2017 - Kanazawa, Japan.